| 189 | 4 | 96 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 分析维持性血液透析(MHD)患者发生肌少症的危险因素。方法 收集2021年1月~2023年2月于六安市中医院行血液透析患者151例。采用亚洲肌少症工作组标准诊断肌少症46例(肌少症组),其他105例患者为非肌少症组。使用改良定量主观整体评估问卷(MQSGA)评估患者的营养状况。对肌少症组和无肌少症组的一般临床资料、实验室指标、透析相关指标进行比较。采用logistic回归进行多元影响因素分析。结果 肌少症组的体质量指数(BMI)、白蛋白、前白蛋白、肌酐、二氧化碳结合力低于非肌少症组,年龄、糖尿病患者占比、MQSGA评估营养不良占比、超敏C反应蛋白高于非肌少症组,组间差异有统计学意义(P<0.05)。logistic多因素回归分析发现年龄、合并糖尿病、营养不良、超敏C反应蛋白、二氧化碳结合力是影响肌少症发生的独立危险因素(P<0.05)。结论 年龄增加、合并糖尿病、营养不良、超敏C反应蛋白升高、二氧化碳结合力降低是影响MHD患者肌少症发生的独立危险因素,需根据MHD患者特点,尽早识别,实施个体化的干预方案。
Abstract:Objective To analyze the risk factors for sarcopenia in maintenance hemodialysis(MHD) patients.Methods Data of 151 patients undergoing hemodialysis in our hospital from January 2021 to February 2023 were collected. According to the criteria of the Asian working group, 46 patients diagnosed with sarcopenia were assigned to the sarcopenia group, while 105 patients without sarcopenia were diagnosed as the non-sarcopenia group. General clinical data, laboratory indicators and dialysis related indicators were compared between the sarcopenia and non-sarcopenia groups. Logistic regression was utilized to conduct a multiple influencing factor analysis.Results BMI, albumin, prealbumin, creatinine, and carbon dioxide binding capacity in the sarcopenia group were lower than those in the non-sarcopenia group, while age, the proportion of diabetes patients, the proportion of malnutrition assessed by MQSGA, and high-sensitivity C-reactive protein were higher than those in the non-sarcopenia group(P < 0.05). Logistic regression analysis showed that age, diabetes, malnutrition, high-sensitivity C-reactive protein and carbon dioxide binding capacity were independent risk factors for myopenia(P < 0.05).Conclusion Age, diabetes, malnutrition, high sensitivity C-reactive protein and low carbon dioxide binding capacity are independent risk factors for myopenia in MHD patients.Early identification based on the characteristics of MHD patients and the implementation of individualized intervention programs are essential.
[1] Cruz-Jentoft AJ,Bahat G,Bauer J,et al.Sarcopenia:revised European consensus on definition and diagnosis[J].Age and Ageing,2019,48(1):16-31.
[2] Bruyère O,Beaudart C,Ethgen O,et al.The health economics burden of sarcopenia:a systematic review[J].Maturitas,2019,119:61-69.
[3] 尤聪瑶,杨铁毅.肌少症诊治研究进展[J].国际骨科学杂志,2022,43(6):357-361.
[4] 万利,王梅.终末期肾病透析患者肌少症的发病机制及诊治进展[J].中国血液净化,2023,22(2):128-132.
[5] Kittiskulnam P,Chertow GM,Carrero JJ,et al.Sarcopenia and its individual criteria are associated,in part,with mortality among patientson hemodialysis[J].Kidney Int,2017,92(1):238-247.
[6] Lin Y,Liou H,Wang C,et al.Impact of sarcopenia and its diagnostic criteria on hospitalization and mortality in chronic hemodialysis patients:a 3-year longitudinal study[J].J Formos Med Assoc,2020,119(7):1219-1229.
[7] Hayashi H,Izumiya Y,Hayashi O,et al.Dynapenia is an independent predictor of cardio-cerebrovascular events in patients undergoing hemodialysis[J].Heart Vessels,2022,37(6):1066-1074.
[8] Ferreira MF,Bohlke M,Pauletto MB,et al.Sarcopenia diagnosis using different criteria as a predictor of early mortality in patients undergoing hemodialysis[J].Nutrition,2022,95:111542.
[9] Chen LK,Woo J,Assantachai P,et al.Asian Working Group for Sarcopenia:2019 consensus update on sarcopenia diagnosis and treatment[J].J Am Med Dir Assoc,2020,21:300-307.
[10] Papadopoulou SK,Tsintavis P,Potsaki P,et al.Differences in the prevalence of sarcopenia in communitydwelling,nursing home and hospitalized indivi-duals.a systematic review and meta-analysis[J].J Nutr Health Aging,2020,24(1):83-90.
[11] 江涛,王新航,张露艺,等.中国老年人肌少症患病率的Meta分析[J].海南医学,2022,33(1):116-123.
[12] Cruz-Jentoft AJ,Sayer AA .Sarcopenia[J].Lancet,2019,393(10191):2636-2646.
[13] 张芳,樊勇.老年人糖尿病与肌少症关系的研究[J].临床医学进展,2023,13(3):4673-4677.
[14] 赵婷,王馥婕,王瑾,等.老年隐性饥饿伴肌肉减少人群的营养干预研究[J].实用老年医学,2022,36(11):1120-1123.
[15] 方吕贵,宣铭杨,杜亚婷,等.尿毒症毒素与慢性肾脏病肌少症的关系研究进展[J].中国血液净化,2022,21(7):521-524.
[16] 杨琦琦,孙颖.肌少症中骨骼肌质量减少的分子机制研究进展[J].临床和实验医学杂志,2020,19(9):1006-1008,后插1.
[17] Raphael KL.Metabolic acidosis and subclinical metabolic acidosis in CKD[J].J Am Soc Nephrol,2018,29(2):376-382.
[18] Quade BN,Parker MD,Occhipinti R.The therapeutic importance of acid-base balance[J].Biochem Pharmacol,2021,183:114278.
[19] 黄瑛,常晶,王晓娟.抗阻运动对肌少症的改善效应[J].中华骨质疏松和骨矿盐疾病杂志,2022,15(2):206-210.
基本信息:
中图分类号:R692.5;R685
引用信息:
[1]胡成云,金莉,周舒梅.维持性血液透析患者发生肌少症的危险因素分析[J].中华保健医学杂志,2024,26(01):75-78.
基金信息:
安徽省重点研究与开发计划项目(201904a07020058)
2024-02-28
2024-02-28